Residency · Residency · Obstetrics Gynecology
Postpartum Hemorrhage: Prevention and Management
Definitions
Primary postpartum hemorrhage refers to blood loss occurring within 24 hours of delivery, while secondary postpartum hemorrhage encompasses abnormal bleeding from 24 hours to 12 weeks postpartum. The quantitative threshold is cumulative blood loss of 1,000 mL or greater, or blood loss accompanied by signs and symptoms of hypovolemia. Previously, thresholds of 500 mL for vaginal delivery and 1,000 mL for cesarean were used, but ACOG revised the definition in 2017 to 1,000 mL for all delivery routes. PPH complicates 3 to 5% of all deliveries and is the leading cause of maternal mortality worldwide and a preventable cause of death.
Etiology: The Four T's
Tone (70%)
Uterine atony is the most common cause of postpartum hemorrhage, accounting for approximately 70% of cases. Risk factors include uterine overdistension from macrosomia, polyhydramnios, or multiple gestation, as well as prolonged labor, chorioamnionitis, high parity, use of uterine relaxants such as magnesium or halogenated anesthetics, and rapid labor.
Trauma (20%)
Trauma accounts for approximately 20% of PPH cases and includes cervical, vaginal, or perineal lacerations, uterine rupture, uterine inversion, episiotomy extension, and hematoma formation in the vulvar, vaginal, or retroperitoneal spaces.
Tissue (10%)
Retained placental tissue or membranes account for approximately 10% of cases. Abnormal placentation in the accreta spectrum and retained blood clots, which disrupt the uterine contractile mechanism, are included in this category.
Thrombin (<1%)
Coagulopathy causes less than 1% of PPH and includes disseminated intravascular coagulation, dilutional coagulopathy, pre-existing bleeding disorders such as von Willebrand disease and platelet disorders, anticoagulant therapy, and acquired coagulopathy from massive hemorrhage, amniotic fluid embolism, or abruption.
Prevention: Active Management of Third Stage (AMTSL)
Active management of the third stage of labor is the most important preventive measure for PPH. The key components include oxytocin administration (10 to 40 units in 500 to 1,000 mL of crystalloid IV, given after delivery of the anterior shoulder or immediately after delivery), controlled cord traction with gentle traction on the cord combined with counter-pressure on the uterus (the Brandt-Andrews maneuver) after signs of placental separation, and uterine massage after placental delivery. AMTSL reduces the incidence of PPH by 60 to 70%.
Quantitative Blood Loss Assessment
Visual estimation of blood loss is inaccurate, underestimating by 33 to 50%. Quantitative blood loss measurement is now the standard of care at most US institutions. The method involves weighing blood-soaked items (where 1 gram equals 1 mL of blood), subtracting the dry weight of the items, and adding measured blood from suction canisters and collection drapes. Calibrated under-buttocks collection drapes improve accuracy further.
<image>Illustration of quantitative blood loss measurement methods including calibrated collection drapes under the patient, weighing of blood-soaked laparotomy sponges and pads on a scale, and suction canister measurement, with the formula: QBL = (wet weight - dry weight) + measured fluid</image>
Stepwise Management Algorithm
Step 1: Initial Assessment and Uterotonic Cascade
The initial response involves calling for help and activating the hemorrhage protocol, establishing large-bore IV access with two 16 to 18 gauge catheters, performing bimanual uterine massage, and identifying the cause using the four T framework. The uterotonic cascade follows a stepwise approach: oxytocin 10 to 40 units IV infusion (which is already running if AMTSL was performed) or 10 units IM as an alternative; methylergonovine 0.2 mg IM, avoiding use in hypertensive patients because of its vasoconstrictive properties; carboprost 0.25 mg IM or intramyometrial every 15 to 90 minutes with a maximum of 8 doses, avoiding use in asthmatic patients; and misoprostol 600 to 1,000 mcg administered buccally, sublingually, or rectally.
| Uterotonic | Dose/Route | Interval | Contraindication |
|---|---|---|---|
| Oxytocin | 10-40 units IV infusion or 10 units IM | Continuous infusion | None significant |
| Methylergonovine | 0.2 mg IM | q2-4 hours | Hypertension |
| Carboprost (15-methyl PGF2α) | 0.25 mg IM or intramyometrial | q15-90 min (max 8 doses) | Asthma |
| Misoprostol (PGE1) | 600-1000 mcg buccal/SL/rectal | Single dose | None significant |
| Tranexamic acid | 1 g IV over 10 min | Repeat at 30 min if needed | Active thromboembolic disease |
Step 2: Exam and Repair
The cervix, vagina, and perineum are inspected for lacerations and repaired as needed. Manual exploration of the uterine cavity is performed to check for retained products. Bedside ultrasound can assist in assessing for retained tissue.
Step 3: Tranexamic Acid (TXA)
Tranexamic acid is administered as 1 g IV over 10 minutes, with a second dose possible at 30 minutes. The WOMAN trial demonstrated that TXA reduces death from PPH when given within 3 hours of delivery onset. TXA is increasingly administered early in the hemorrhage cascade and has not been associated with a significant increase in thromboembolic events.
Step 4: Intrauterine Tamponade
Balloon Tamponade
The Bakri balloon is filled with 300 to 500 mL of saline inside the uterine cavity. A condom catheter serves as an alternative in resource-limited settings. The "tamponade test" is a useful clinical assessment: if bleeding stops with balloon inflation, surgical intervention may be avoided. The balloon is left in place for 12 to 24 hours and removed gradually with an oxytocin infusion running.
Vacuum-Induced Uterine Tamponade (Jada Device)
The Jada device applies low-level vacuum through an intrauterine device, promoting uterine contraction and tamponade. It has a rapid onset of effect and is gaining widespread adoption. Multicenter data show a high success rate with reduced need for surgical intervention.
Step 5: Surgical Management
Surgical options include uterine compression sutures such as the B-Lynch suture (a vertical compression suture around the uterus), Cho sutures (horizontal mattress sutures through the uterine wall), and O'Leary sutures (bilateral uterine artery ligation). Uterine artery ligation using the O'Leary stitch ligates the ascending branches of the uterine arteries bilaterally. Internal iliac artery ligation is rarely performed because it is technically demanding. Uterine artery embolization performed by interventional radiology is effective when the patient is stable enough for transfer to the IR suite.
Step 6: Hysterectomy
Hysterectomy is the definitive treatment for refractory PPH and should not be delayed when other measures have failed and hemorrhage is life-threatening. Supracervical hysterectomy is faster, while total hysterectomy is preferred when the lower segment is the bleeding source. The decision to proceed to hysterectomy reflects appropriate clinical judgment, not failure.
<image>Stepwise algorithm for postpartum hemorrhage management organized as an escalating pyramid: base level shows uterine massage and uterotonics, next level shows exam/repair and TXA, followed by tamponade (balloon or vacuum), then surgical interventions (compression sutures, artery ligation), and apex showing hysterectomy as definitive treatment</image>
Massive Transfusion Protocol (MTP)
Activation Criteria
The massive transfusion protocol should be activated when estimated blood loss reaches 1,500 mL or more with ongoing rapid bleeding, when hemodynamic instability persists despite fluid resuscitation, when clinical signs of coagulopathy appear, or when a need for 4 or more units of packed red blood cells is anticipated.
Transfusion Strategy
The 1:1:1 ratio of packed red blood cells to fresh frozen plasma to platelets, adopted from trauma literature, is applied to obstetric hemorrhage. Uncrossmatched O-negative blood is used when type-specific blood is not available. Cryoprecipitate is administered when fibrinogen falls below 200 mg/dL, with each unit raising fibrinogen by approximately 10 mg/dL and a typical dose of 10 units. Calcium supplementation is necessary because citrate in blood products chelates calcium, and levels should be monitored and replaced. Hypothermia must be avoided through the use of blood warmers.
Laboratory Monitoring During MTP
CBC, fibrinogen, PT/INR, and PTT should be checked every 30 to 60 minutes during active hemorrhage. Point-of-care testing such as i-STAT or viscoelastic testing with TEG or ROTEM enables rapid assessment. Targets include fibrinogen above 200 mg/dL, platelets above 50,000, and INR below 1.5.
Secondary (Late) PPH
Causes
The most common cause of secondary PPH is retained products of conception. Other causes include endometritis, subinvolution of the placental site, inherited coagulopathy such as von Willebrand disease, and arteriovenous malformation, which is rare.
Management
Management includes ultrasound to assess for retained products, uterotonics such as methylergonovine and misoprostol, antibiotics if infection is suspected, uterine aspiration or curettage for retained products, and uterine artery embolization for arteriovenous malformation or refractory bleeding.
Hemorrhage Preparedness
Risk Assessment
PPH risk should be assessed at admission and updated as labor progresses. Risk stratification tools such as the CMQCC OB Hemorrhage Toolkit guide preparation. Blood products, IV access, and team availability are arranged based on the risk level.
Safety Bundles (AIM Initiative)
The AIM initiative organizes hemorrhage preparedness into four domains. Readiness includes maintaining a hemorrhage cart, a massive transfusion protocol, and conducting simulation drills. Recognition and Prevention encompass risk assessment, active management of the third stage, and quantitative blood loss measurement. Response involves a standardized hemorrhage protocol, staged escalation, and team communication. Reporting and Systems Learning includes debriefing after events, tracking outcomes, and identifying system gaps.
Clinical Pearls
Uterine atony causes 70% of PPH, and bimanual massage with uterotonics should be the immediate first steps.
Quantitative blood loss measurement has replaced visual estimation as the standard. One gram of weight equals 1 mL of blood.
TXA should be administered early, within 3 hours of delivery onset. The WOMAN trial demonstrated a mortality benefit.
The tamponade test with an intrauterine balloon helps determine whether surgical intervention can be avoided.
Vacuum-induced tamponade with the Jada device is emerging as a rapid, effective alternative to balloon tamponade.
Hysterectomy should not be delayed when hemorrhage is refractory to other measures. Delayed decision-making is a leading contributor to PPH-related maternal death.
Fibrinogen is the first coagulation factor to become critically depleted in obstetric hemorrhage. It should be monitored closely and replaced aggressively with cryoprecipitate.
Every labor unit should have a standardized hemorrhage protocol with regular simulation drills.
References
- ACOG Practice Bulletin No. 183: Postpartum Hemorrhage (2017, reaffirmed 2023)
- WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality. Lancet. 2017;389:2105-2116
- Main EK et al. National partnership for maternal safety: consensus bundle on obstetric hemorrhage. Obstet Gynecol. 2015;126:155-162
- California Maternal Quality Care Collaborative (CMQCC). OB Hemorrhage Toolkit v3.0 (2022)
- Anger HA et al. Vacuum-induced hemorrhage control for postpartum hemorrhage (Jada). Obstet Gynecol. 2022
- Pacheco LD et al. Medical management of postpartum hemorrhage: an update. Semin Perinatol. 2019
